SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Vivos Therapeutics,
Inc.
(Name of Issuer)
Common Stock, par
value $0.0001 per share
(Title of Class of Securities)
92859E207
(CUSIP Number)
September 19, 2024
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
☐ Rule
13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 92859E207 |
|
13G |
|
Page 2 of 10 Pages |
1. |
NAMES OF REPORTING PERSONS
Ionic Ventures, LLC |
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
California, United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
0 |
6. |
SHARED VOTING POWER
412,064 (1) |
7. |
SOLE DISPOSITIVE POWER
0 |
8. |
SHARED DISPOSITIVE POWER
412,064 (1) |
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,064 (1) |
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.7% (1) |
12. |
TYPE OF REPORTING PERSON (see instructions)
OO |
|
(1) |
As more fully described in Item 4 of this Statement on Schedule 13G (this “Schedule 13G”), such shares and percentage are based on 4,765,300 outstanding shares of common stock, par value $0.0001 per share, of the issuer (the “Common Stock”), as reported in the prospectus supplement to the registration statement on Form S-3 (File No. 333-262554), filed by the issuer with the U.S. Securities and Exchange Commission on September 20, 2024 (the “Prospectus Supplement”). |
CUSIP No. 92859E207 |
|
13G |
|
Page 3 of 10 Pages |
1. |
NAMES OF REPORTING PERSONS
Ionic Management, LLC |
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware, United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
0 |
6. |
SHARED VOTING POWER
412,064 (1) |
7. |
SOLE DISPOSITIVE POWER
0 |
8. |
SHARED DISPOSITIVE POWER
412,064 (1)
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,064 (1) |
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.7% (1) |
12. |
TYPE OF REPORTING PERSON (see instructions)
OO |
|
(1) |
As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement. |
CUSIP No. 92859E207 |
|
13G |
|
Page 4 of 10 Pages |
1. |
NAMES OF REPORTING PERSONS
Brendan O’Neil |
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
0 |
6. |
SHARED VOTING POWER
412,064 (1) |
7. |
SOLE DISPOSITIVE POWER
0 |
8. |
SHARED DISPOSITIVE POWER
412,064 (1) |
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,064 (1) |
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.7% (1) |
12. |
TYPE OF REPORTING PERSON (see instructions)
IN |
|
(1) |
As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement. |
CUSIP No. 92859E207 |
|
13G |
|
Page 5 of 10 Pages |
1. |
NAMES OF REPORTING PERSONS
Keith Coulston |
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ☒
(b) ☐ |
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
0 |
6. |
SHARED VOTING POWER
412,064 (1) |
7. |
SOLE DISPOSITIVE POWER
0 |
8. |
SHARED DISPOSITIVE POWER
412,064 (1) |
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,064 (1) |
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.7% (1) |
12. |
TYPE OF REPORTING PERSON (see instructions)
IN |
|
(1) |
As more fully described in Item 4 of this Schedule 13G, such shares and percentage are based on 4,765,300 shares of Common Stock outstanding, as reported in the Prospectus Supplement. |
CUSIP No. 92859E207 |
|
13G |
|
Page 6 of 10 Pages |
Item 1(a). Name of Issuer:
Vivos Therapeutics, Inc. (the “Issuer”).
Item 1(b). Address of Issuer’s Principal
Executive Offices:
The Issuer’s principal executive office is
located at 7921 Southpark Plaza, Suite 210, Littleton, CO 80120.
Item 2(a). Names of Persons Filing:
|
(i) Ionic Ventures LLC, a California limited liability company (“Ionic”); |
|
|
|
(ii) Ionic Management, LLC, a Delaware limited liability company (“Ionic Management”); |
|
|
|
(iii) Brendan O’Neil (“Mr. O’Neil”); and |
|
|
|
(iv) Keith Coulston (“Mr. Coulston”). |
The foregoing persons are hereinafter collectively
referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting
Persons are made on information and belief after making inquiry to the appropriate party.
The Reporting Persons have entered into a Joint
Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which such Reporting Persons have agreed
to file this Schedule 13G and all subsequent amendments to the Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)
of the Act.
The filing of this Schedule 13G should not be construed
in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of the common stock reported
herein.
Item 2(b). Address of Principal Business Office
or, if none, Residence:
The principal business address of each of the Reporting
Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.
Item 2(c). Citizenship:
Ionic is a limited liability company organized
under the laws of the State of California. Ionic Management is a limited liability company organized under the laws of the State
of Delaware. Each of Mr. Coulston and Mr. O’Neil is a citizen of the United States.
Item 2(d). Title of Class of Securities:
The title of the class of securities to which this
Schedule 13G relates is the Issuer’s common stock, par value $0.0001 per share (the “Common Stock”).
CUSIP No. 92859E207 |
|
13G |
|
Page 7 of 10 Pages |
Item 2(e). CUSIP Number: 92859E207
Item 3. If This Statement is Filed Pursuant
to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
Not applicable.
Item 4. Ownership.
The information required by this item with respect
to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and is incorporated herein
by reference for each such Reporting Person. The ownership percentages reported are based on 4,765,300 shares of Common Stock outstanding,
as reported in the prospectus supplement to the registration statement on Form S-3 (File No. 333-262554), filed by the Issuer with
the U.S. Securities and Exchange Commission on September 20, 2024.
As of September 24, 2024, Ionic is the beneficial
owner of 412,064 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote
the Shares beneficially owned by it, which power may be exercised by its manager, Ionic Management. Each of the managers of Ionic
Management, Mr. O’Neil and Mr. Coulston, has shared power to vote and/or dispose of the Shares beneficially owned by Ionic
and Ionic Management. Neither Mr. O’Neil nor Mr. Coulston directly owns the Shares. By reason of the provisions of Rule 13d-3
of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares which are beneficially owned
by each of Ionic and Ionic Management, and Ionic Management may be deemed to beneficially own the Shares which are beneficially
owned by Ionic.
Item 5. Ownership of Five Percent or Less of
a Class.
Not applicable.
Item 6. Ownership of More than Five Percent
on Behalf of Another Person.
Not applicable.
CUSIP No. 92859E207 |
|
13G |
|
Page 8 of 10 Pages |
Item 7. Identification and Classification of
the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of
Members of the Group.
See Exhibit 1 filed herewith.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below each of the Reporting Persons
certify that, to the best of each of their knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities
solely in connection with a nomination under § 240.14a-11.
CUSIP No. 92859E207 |
|
13G |
|
Page 9 of 10 Pages |
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
Date: September 24, 2024 |
IONIC VENTURES, LLC |
|
|
|
By: |
Ionic Management, LLC, |
|
|
its Manager |
|
|
|
By: |
/s/ Keith Coulston |
|
|
Name: Keith Coulston |
|
|
Title: Manager |
|
|
|
IONIC MANAGEMENT, LLC |
|
|
|
By: |
/s/ Keith Coulston |
|
|
Name: Keith Coulston |
|
|
Title: Manager |
|
|
|
|
/s/ Brendan O’Neil |
|
Brendan O’Neil |
|
|
|
|
/s/ Keith Coulston |
|
Keith Coulston |
CUSIP No. 92859E207 |
|
13G |
|
Page 10 of 10 Pages |
EXHIBIT 1
JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the
foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement
on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and
accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness
and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such
information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number
of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together
constitute one and the same instrument.
Date: September 24, 2024 |
IONIC VENTURES, LLC |
|
|
|
By: Ionic Management, LLC, |
|
its Manager |
|
|
|
By: |
/s/ Keith Coulston |
|
|
Name: Keith Coulston |
|
|
Title: Manager |
|
|
|
IONIC MANAGEMENT, LLC |
|
|
|
By: |
/s/ Keith Coulston |
|
|
Name: Keith Coulston |
|
|
Title: Manager |
|
|
|
|
/s/ Brendan O’Neil |
|
Brendan O’Neil |
|
|
|
|
/s/ Keith Coulston |
|
Keith Coulston |
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Jan 2024 to Jan 2025